Thomas Catinazzo Sells 20,791 Shares of Relay Therapeutics, Inc. (NASDAQ:RLAY) Stock

Relay Therapeutics, Inc. (NASDAQ:RLAY) CFO Thomas Catinazzo sold 20,791 shares of Relay Therapeutics stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $4.42, for a total transaction of $91,896.22. Following the transaction, the chief financial officer now owns 379,431 shares of the company’s stock, valued at $1,677,085.02. This represents a 5.19 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Thomas Catinazzo also recently made the following trade(s):

• On Tuesday, January 28th, Thomas Catinazzo sold 36,036 shares of Relay Therapeutics stock. The shares were sold at an average price of $4.63, for a total transaction of $166,846.68.
• On Friday, December 27th, Thomas Catinazzo sold 4,865 shares of Relay Therapeutics stock. The stock was sold at an average price of $4.42, for a total value of $21,503.30.

Relay Therapeutics Stock Down 1.5 %

Relay Therapeutics stock opened at $4.47 on Friday. The firm has a 50 day moving average price of $4.53 and a 200-day moving average price of $6.11. Relay Therapeutics, Inc. has a twelve month low of $3.50 and a twelve month high of $11.16. The company has a market capitalization of $748.19 million, a P/E ratio of -1.71 and a beta of 1.60.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings data on Wednesday, November 6th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.77) by $0.14. Relay Therapeutics’s quarterly revenue was down 100.0% on a year-over-year basis. During the same period in the prior year, the business earned ($0.54) EPS. Equities analysts expect that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Leerink Partners cut their target price on Relay Therapeutics from $19.00 to $18.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 4th. HC Wainwright reiterated a “buy” rating and issued a $16.00 target price on shares of Relay Therapeutics in a research note on Tuesday, January 14th. Finally, JMP Securities reissued a “market outperform” rating and set a $21.00 price target on shares of Relay Therapeutics in a research report on Thursday, December 12th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.50.

Institutional Investors Weigh In On Relay Therapeutics

Large investors have recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC boosted its position in Relay Therapeutics by 6.6% during the third quarter. Allspring Global Investments Holdings LLC now owns 41,203 shares of the company’s stock worth $292,000 after purchasing an additional 2,547 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Relay Therapeutics during the 3rd quarter valued at approximately $63,000. China Universal Asset Management Co. Ltd. boosted its holdings in Relay Therapeutics by 37.8% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 35,491 shares of the company’s stock worth $146,000 after buying an additional 9,740 shares during the period. Portland Investment Counsel Inc. purchased a new position in Relay Therapeutics in the 3rd quarter valued at approximately $71,000. Finally, XTX Topco Ltd raised its holdings in Relay Therapeutics by 27.9% during the 3rd quarter. XTX Topco Ltd now owns 47,271 shares of the company’s stock valued at $335,000 after acquiring an additional 10,311 shares during the period. Hedge funds and other institutional investors own 96.98% of the company’s stock.

About Relay Therapeutics

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.